Logo image of INCR

INTERCURE LTD (INCR) Stock Fundamental Analysis

NASDAQ:INCR - IL0011063760 - Common Stock

1.58 USD
+0 (+0.27%)
Last: 9/5/2025, 8:22:38 PM
Fundamental Rating

3

Overall INCR gets a fundamental rating of 3 out of 10. We evaluated INCR against 195 industry peers in the Pharmaceuticals industry. INCR may be in some trouble as it scores bad on both profitability and health. INCR has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year INCR has reported negative net income.
INCR had a negative operating cash flow in the past year.
In multiple years INCR reported negative net income over the last 5 years.
In multiple years INCR reported negative operating cash flow during the last 5 years.
INCR Yearly Net Income VS EBIT VS OCF VS FCFINCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

INCR's Return On Assets of -8.62% is fine compared to the rest of the industry. INCR outperforms 68.21% of its industry peers.
The Return On Equity of INCR (-14.90%) is better than 71.79% of its industry peers.
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INCR Yearly ROA, ROE, ROICINCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

INCR has a Gross Margin (14.90%) which is in line with its industry peers.
In the last couple of years the Gross Margin of INCR has declined.
INCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
INCR Yearly Profit, Operating, Gross MarginsINCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

INCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
INCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INCR Yearly Shares OutstandingINCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
INCR Yearly Total Debt VS Total AssetsINCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.58, we must say that INCR is in the distress zone and has some risk of bankruptcy.
INCR has a Altman-Z score (0.58) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.23 indicates that INCR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.23, INCR perfoms like the industry average, outperforming 44.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC12.56%
INCR Yearly LT Debt VS Equity VS FCFINCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.85 indicates that INCR should not have too much problems paying its short term obligations.
With a Current ratio value of 1.85, INCR is not doing good in the industry: 61.54% of the companies in the same industry are doing better.
INCR has a Quick Ratio of 1.39. This is a normal value and indicates that INCR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.39, INCR is not doing good in the industry: 63.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.39
INCR Yearly Current Assets VS Current LiabilitesINCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

INCR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.71%.
INCR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.82%.
INCR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 92.97% yearly.
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%

3.2 Future

INCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 561.44% yearly.
Based on estimates for the next years, INCR will show a very strong growth in Revenue. The Revenue will grow by 40.52% on average per year.
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
INCR Yearly Revenue VS EstimatesINCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
INCR Yearly EPS VS EstimatesINCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

INCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
INCR is valuated reasonably with a Price/Forward Earnings ratio of 8.91.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INCR indicates a rather cheap valuation: INCR is cheaper than 87.18% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of INCR to the average of the S&P500 Index (22.69), we can say INCR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.91
INCR Price Earnings VS Forward Price EarningsINCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INCR Per share dataINCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as INCR's earnings are expected to grow with 561.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y561.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERCURE LTD

NASDAQ:INCR (9/5/2025, 8:22:38 PM)

1.58

+0 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-28 2025-08-28
Earnings (Next)N/A N/A
Inst Owners5.35%
Inst Owner Change0.4%
Ins Owners30.2%
Ins Owner Change0%
Market Cap86.13M
Analysts82.86
Price TargetN/A
Short Float %0.09%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.91
P/S 1.2
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)0.18
Fwd EY11.22%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS1.31
BVpS2.5
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.9%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.4%
Cap/Sales 2.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.39
Altman-Z 0.58
F-Score2
WACC12.56%
ROIC/WACCN/A
Cap/Depr(3y)73.35%
Cap/Depr(5y)210.09%
Cap/Sales(3y)2.61%
Cap/Sales(5y)9.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-255.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year271.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.79%
OCF growth 3YN/A
OCF growth 5YN/A